The artificial intelligence-powered startup, AlphaSense, has announced a significant leap in its valuation to a staggering $2.5 billion. This leap follows its recent acquisition of $150 million during the latest series E funding round, underscoring the booming investor confidence in AI enterprises.
BOND, a prominent technology investment firm, spearheaded the funding. The round also saw continued support from industry titans such as Alphabet’s CapitalG, Viking Global Investors, and Goldman Sachs.
AlphaSense intends to channel this fresh capital towards expanding its searchable business content repository. The company also hints at strategic acquisitions, aiming to broaden the spectrum of their platform capabilities.
Jack Kokko, AlphaSense’s CEO, in an interview with Reuters, shared the company’s robust financial position. “We have more capital at our disposal than we ever envisaged,” he remarked, although he remained discreet about any impending Initial Public Offering (IPO) plans.
At the heart of AlphaSense’s offering is its adeptness at extracting pertinent data from diverse sources, encompassing equity research, earnings calls, company filings, and news. Mary Meeker, General Partner at BOND, emphasized the industry sentiment, stating, “Tools powered by AI, adept at drawing insights from vast data, are witnessing rapid growth.”
Kokko also alluded to the company’s aspirations of delving into generative AI, signaling possible product diversification.
Notably, earlier this year, AlphaSense secured a whopping $100 million, with Alphabet’s venture arm, CapitalG, taking the lead. This round had valued the company at an impressive $1.8 billion.
The AI space has been a hotbed for investments, with tech giants like Microsoft Corp. earmarking massive sums, as seen with their recent commitment to invest up to $10 billion in ChatGPT’s parent company.
Established in 2011, New York’s very own AlphaSense Inc. has made significant strides with its AI-optimized search engine. Beyond business, its platform has been instrumental for cancer researchers and innovative consultants alike.
